Screening and Identiifcation of Novel Drug-resistant Genes in CD133+and CD133-Lung Adenosarcoma Cells Using cDNA Microarray
10.3779/j.issn.1009-3419.2014.06.01
- VernacularTitle:基因芯片筛选CD133+/CD133-肺腺癌细胞中新的耐药基因
- Author:
WANG HONGYAN
1
;
ZHENG SHAOQIU
;
TU YONGSHENG
;
ZHANG YAJIE
Author Information
1. 广州医科大学病理教研室
- Keywords:
CD133;
Lung neoplasms;
Multi-drug resistant;
Drug-resistant microarray
- From:
Chinese Journal of Lung Cancer
2014;(6):437-443
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Cancer stem cells (CSCs) are responsible for multi-drug resistance in tu-mors. CD133 is a known biomarker of CSCs. hTe aim of this study is to screen for drug-resistant differentially expressed genes in CD133+and CD133-lung cancer cells and to identify novel lung tumor drug-resistant genes. Methods Magnetic activated cell sorting was used to isolate CD133+and CD133-cells from human lung cancer cell line A549, and drug-resistant microarray was used to detect drug-resistant genes in the these cells. RT-qPCR was used to examine the expression of six lung tumor drug-resistant genes in pre-and post-chemotherapeutic A549 cells. Results A total of 31 differentially expressed genes were screened by microar-ray analysis. Of these genes, 30 were upregulated and one was downregulated in CD133+cells compared with CD133-cells. Re-sults were veriifed by RT-qPCR. CYP2C19, CYP2D6, CYP2E1, GSK3α, PPARα, and PPARβ/δwere signiifcantly upregulated atfer the A549 cells were treated with 1.97μg/mL DDP or 0.61μg/mL doxorubicin for 48 h. Conclusion hTe drug resistance of lung adenosarcoma may be correlated with 31 differentially expressed genes screened by drug-resistant microarray. CYP2C19, CYP2D6, CYP2E1, GSK3α, PPARα, and PPARβ/δmight be novel lung adenosarcoma drug-resistant genes.
